Open AccessLomustine (CCNU) for the Treatment of Resistant Lymphoma in Dogs
Author(s) -
Moore Antony S.,
London Cheryl A.,
Wood Carrie A.,
Williams Laurel E.,
Cotter Susan M.,
L'Heureux Deborah A.,
Frimberger Angela E.
Publication year - 1999
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.1999.tb01452.x
Subject(s) - lomustine , medicine , neutropenia , lymphoma , chemotherapy , leukopenia , gastroenterology , nitrosourea , surgery , vincristine , cyclophosphamide
Forty‐three dogs with lymphoma that had relapsed or had failed to achieve complete remission to previous chemotherapy were treated with lomustine (1‐(2‐chloroethyl)‐3‐cyclohexyl‐l‐nitrosourea [CCNU]) at a dosage of 90–100 mg/m 2 body surface area PO every 3 weeks. Durable complete or partial responses occurred in 11 dogs for a median of 86 days. The acutely dose‐limiting toxicosis was neutropenia 7 days after administration, resulting in a recommended dosage of 90 mg/m 2 . Cumulative thrombocy‐topenia occurred in dogs receiving continued CCNU treatment, and a dose interval of 3 weeks may be too short for continued administration of this drug. Toxicoses evident as fever or central nervous system signs or renal damage were uncommon or rare. CCNU is effective in the treatment of relapsed lymphoma.